
WHAT IS CLAIMED IS:

1	1. A method of screening drug candidates comprising:
2	a) providing a cell that expresses an expression profile gene selected from the
3	group consisting of an expression profile gene set forth in Table 1 or Table 2 or fragment
4	thereof;
5	b) adding a drug candidate to said cell; and
6	c) determining the effect of said drug candidate on the expression of said
7	expression profile gene.
11. 2. 2. 2. 3. 11. 11. 11. 11. 11. 11. 11. 11. 11.	2. A method according to claim 1 wherein said determining comprises comparing the level of expression in the absence of said drug candidate to the level of expression in the presence of said drug candidate.
NJ 231	3. A method of screening for a bioactive agent capable of binding to a
±.2	colorectal cancer modulator protein (colorectal cancer modulator protein), wherein said
riig	colorectal cancer modulator protein is encoded by a nucleic acid selected from the group
13 13 13 15	consisting of a nucleic acid of Table 1 or Table 2 or a fragment thereof, said method comprising:
6	a) combining said colorectal cancer modulator protein and a candidate
7	bioactive agent; and
8	b) determining the binding of said candidate agent to said colorectal cancer
9	modulator protein.
1	4. A method for screening for a bioactive agent capable of modulating the
2	activity of a colorectal cancer modulator protein, wherein said colorectal cancer modulator
3	protein is encoded by a nucleic acid selected from the group consisting of a nucleic acid of
4	Table 1 or Table 2 or a fragment thereof, said method comprising:
5	a) combining said colorectal cancer modulator protein and a candidate
6	bioactive agent; and





acid of Table 1 or Table 2 or a fragment thereof.



2	antibody.
1	20. The antibody of Claim 18, wherein said antibody is a humanized
2	antibody.
1	21. The antibody of Claim 18, wherein said antibody is an antibody fragment.
1	22. A biochip comprising one or more nucleic acid segments selected from
2	the group consisting of a nucleic acid of Table 1 or Table 2 or a fragment thereof, wherein
3	said biochip comprises fewer than 1000 nucleic acid probes.
	23. A nucleic acid having a sequence at least 95% homologous to a sequence
(j)2 Lij	of a nucleic acid of Table 1 or Table 2 or its complement.
	24. A nucleic acid which hybridizes under high stringency to a nucleic acid of
[l <u>/2</u> [])	Table 1 or Table 2 or its complement.
a	25. A polypeptide encoded by the nucleic acid of Claim 23 or 24.
	26. A method of eliciting an immune response in an individual, said method
(12	comprising administering to said individual a composition comprising the polypeptide of
3	Claim 25 or a fragment thereof.
1	27. A method of eliciting an immune response in an individual, said method
2	comprising administering to said individual a composition comprising a nucleic acid
3	comprising a sequence of a nucleic acid of Table 1 or Table 2 or a fragment thereof.
1	28. A method of determining the prognosis of an individual with colorectal
2	cancer comprising:
3	a) determining the expression of one or more genes selected from the group
4	consisting of a nucleic acid of Table 1 or Table 2 or a fragment thereof in a first tissue type of
5	a first individual; and
6	b) comparing said expression of said gene(s) from a second normal tissue type
7	from said first individual or a second unaffected individual;

19. The antibody of Claim 18, wherein said antibody is a monoclonal

- 8 wherein a substantial difference in said expression indicates a poor prognosis.
- 1 29. A method of treating colorectal cancer comprising administering to an
- 2 individual having colorectal cancer an antibody to a colorectal cancer modulator protein or
- 3 fragment thereof conjugated to a therapeutic moiety.
- 1 30. The method of Claim 29, wherein said therapeutic moiety is a cytotoxic
- 2 agent.

Starts (first) (first (first) (first)

fij

ΓIJ

- 1 31. The method of Claim 29, wherein said therapeutic moiety is a
- 2 radioisotope.